ArticleBritish journal of haematology2026
Machine learning-driven investigation on liquid-liquid phase separation-related prognostic signature in diffuse large B-cell lymphoma.
Article in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma and is characterized by substantial heterogeneity. This study aimed to develop a liquid-liquid phase separation (LLPS)-related prognostic model to improve risk stratification. Transcriptomic and clinical data from four cohorts (n = 768) were analysed. Multiple machine learning algorithms were applied to identify prognostic LLPS-related genes (LRGs) and construct a 6-LRG model. Model performance was assessed using survival analysis, time-dependent receiver operating characteristic curves and multivariable modelling. Additional analyses were conducted to explore potential biological and microenvironmental differences between risk groups. The 6-LRG model stratified patients into groups with significantly different overall survival across datasets, with 1-year area under curve (AUCs) ranging from 0.661 to 0.820, 3-year AUCs from 0.683 to 0.779 and 5-year AUCs from 0.711 to 0.807. The 6-LRG model remained independent of established clinical variables and improved risk prediction when integrated into a nomogram. Distinct biological and immune characteristics were observed between groups. The 6-LRG model may provide additional prognostic information in DLBCL and generates hypotheses regarding underlying biological mechanisms. However, prospective validation in larger populations is essential before any implementation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.